Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of XW003 injection in obese adults with obstructive sleep apnea receiving PAP
ChiCTR2600131340Phase 3Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obstructive sleep apnea hypopnea syndrome (OSAHS) and obesity comparing XW003 injection group with Placebo group (2 arms). Primary endpoint: Apnea-hypopnea index. Started Mar 2026; status: recruiting.
02
Drugs
ecnoglutide
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)obesity
Beyond the preview
Go deeper on ChiCTR2600131340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131340.